Introduction {#Sec1}
============

In cancer cells, considerable number of metabolic enzymes and intermediates are deregulated^[@CR1]^. Acetyl-coenzyme A (AcCoA) is a key metabolic intermediate in anabolic and catabolic pathways, and plays a critical role in biomass production^[@CR2],[@CR3]^. AcCoA homeostasis directly affects the level of histone acetylation, which contributes to transcriptional and posttranslational gene expression regulations^[@CR4]^. Hence, AcCoA biosynthesis is crucial for cancer cell metabolism, especially under metabolic stress^[@CR5]^.

AcCoA were basically generated from two pathways: one is mediated by ATP citrate lyase, which cleaved citrate into oxaloacetate and acetyl-CoA, and the other is mediated by acetyl-CoA synthetase short chain family (ACSS), which ligates acetate and CoA^[@CR6]^. ACSS family contains three family members, ACSS1, ACSS2, and ACSS3. ACSS1 was originally found to be required for acetate uptake and cell survival in hepatocellular carcinoma^[@CR7]^. In addition, ACSS1 was involved in cell survival and tumor growth of melanoma cells^[@CR8]^. Most recently, it has been proposed that ACSS family proteins distinct heterogeneity of hepatocellular carcinoma in a metabolic manner^[@CR9]^. Among the three ACSSs, ACSS2 was most extensively studied. Reports showed that ACSS2 precipitated in lipid metabolism and regulated carcinogenesis in hepatocellular carcinoma^[@CR7],[@CR10]^, glioblastoma^[@CR11]^, breast cancer^[@CR6]^, prostate cancer^[@CR6]^, and bladder cancer^[@CR12]^. On the other hand, little is known about the function of newly identified ACSS member, ACSS3. It has been proposed that ACSS3 acts as an important prognosis biomarker in gastric cancer^[@CR13]^ and ACSS3 serves as a biomarker to stratify subtypes of hepatocellular carcinoma^[@CR9]^. However, the biological function of ACSS3 has not been verified in cancer cells yet.

As solid tumors usually confronted unfavorable environments where oxygen and nutrition were limited, alterative metabolic pathways were aberrantly activated to meet the demands for biomass production in cancer cells^[@CR14]^. Under hypoxia status, AcCoA production from glucose was diminished and molecular tools have been developed to trace the metabolism of AcCoA^[@CR15],[@CR16]^. It has been illustrated that acetate serve as an alternative carbon origin under metabolic stress conditions^[@CR6],[@CR17]^. Therefore, it is of special significance to further validate the participation of ACSS proteins in tumorigenesis and evaluate the role ACSS proteins in alternative utilization of carbon sources.

Bladder urothelial carcinoma (BLCA) is the most common malignancy in the urinary tract, which lead to \~150,000 death worldwide each year^[@CR18]^. Even though only \~25% of BLCA progressed into muscle invasive BLCA, half of the advanced cancers further metastasize^[@CR19]^. What make the situation worse is that no well-defined prognostic marker for BLCA is currently available^[@CR20]^. Hence, identification of proteins, especially metabolic enzymes, facilitates carcinogenesis of BLCA provides novel insights and potential therapeutic targets for BLCA.

Here we quantified the AcCoA metabolism in bladder cancer (BLCA) cells under normoxia and hypoxia, and evaluated the role ACSS3 in AcCoA metabolism during metabolic stress in bladder cancer cell lines. Moreover, we further dissected the function of ACSS3 in bladder cancer cell growth in vitro and in vivo. Importantly, we analyzed our clinical data and revealed an oncogenic role of ACSS3 in bladder cancer.

Material and methods {#Sec2}
====================

Cell culture {#Sec3}
------------

SV-HUC-1, UMUC3, T24 cells were purchased from the American Type Culture Collection. SV-HUC-1 cell line was maintained in F-12K Medium (HyClone). UMUC3 cell line was cultured in Eagle's Minimum Essential Medium (HyClone). T24 cell line was cultured in McCoy's 5a Medium (HyClone). All the cell lines were cultured in base medium supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Gibco) at 37 °C and 5% CO~2~.

^13^C Enrichment in lipogenic AcCoA detection {#Sec4}
---------------------------------------------

Fatty acid labeling assay was performed as previously described^[@CR21]^. Briefly, cells were maintained in culture medium containing 2 mM glutamine. Cells were plated in six-well plates overnight before changing medium. Medium were changedto Dulbecco's modified Eagle medium with ^13^C-labeled glucose (10 mM), ^13^C-glutamine (2 mM), and 13C-acetate for 48--72 h. Cells were washed with phosphate-buffered saline (PBS), add 0.75 mL of methanol : PBS (1 : 1), and place the plate at −20 °C for 10 min. To extract fatty acids, we scraped cells and transferred to glass tubes, added 0.5 mL cold chloroform, and vortexed for 1 min and dried under nitrogen gas. Then, add toluene (80 μl), methanol (600 μl), and methanolic-HCl (120 μl) to each tube, vortex, and incubate at 100 °C for 60 min. Water (0.4 ml) and hwxane (0.3 ml) were added to samples after reducing to room temperature, vortex and analyzed the top hexane phase by Gas Chromatography-Mass Spectrometer (GC-MS). The carbon sources of lipogenic AcCoA was determined by computed binomial distributions as previously described^[@CR21]^.

Quantification of medium acetate {#Sec5}
--------------------------------

For acetate derivatization, 200 μl cell culture medium was collected into a 2 mL microfuge tube, followed by 40 μl 2H3-acetate (1 mM), 1-propanol (50 μl), and pyridine (50 μl). Tube was put on ice for 5 min and 100 μl NaOH (1 M), 30 μl methyl-chloroformate were added. After overtaxing for 20 s, add 300 μl of tert-butyl methyl ether (MTBE) to the tube and vortex again. The samples were then centrifuged at 10,000 × *g* for 5 min. The upper layer was transferred to GC-MS vials and analyzed with an Agilent 7890B GC system and 7000 Triple Quadrupole GC-MS system. Data were collected and analyzed as previously described^[@CR22]^.

Histones and histone-bound acetate extraction {#Sec6}
---------------------------------------------

Cells were collected and washed with cold PBS supplemented with sodium butyrate (10 mM) and nicotinamide (50 mM). Extraction of nuclei was followed as described previously^[@CR23]^. Histones were separated with SDS-polyacrylamide gel electrophoresis (PAGE) and detected with acetyl-histone-specific antibodies. Isolated histones were placed at 95 °C overnight with 10 M NaOH, then added with hydrochloric acid for GC-MS.

Transfection of small interfering RNA and small hairpin RNA {#Sec7}
-----------------------------------------------------------

To construct inducible knockdown cell lines, two different small hairpin RNA (shRNA) sequences target ACSS3 and a control shRNA were cloned into pLKO-Puro plasmids. The sequences of shRNA are as follows: shACSS3-1: 5′-GGGTTACCTAAGGGTGTGGAAtt-3′, shACSS3-2: 5′-GAAAAGATATAAATGCAAGAAtt-3′. Lentivirus production and infection were generated as previously described in 293T cells. 293T cells were seeded at 10^5^ cells per well and were transfected with plasmids. Viral supernatant was harvested 48 h after transfection. Cells were infected for 12 h and cultured for another 24 h and collected. Same sequences were synthesized as small interfering RNA (siRNA) and siRNAs were transfected with Lipofectamine 2000 (Invitrogen). Cells were collected 2 days post siRNA transfection.

Tumor xenografts {#Sec8}
----------------

All animals were maintained in specific pathogen-free conditions according to the recommendation of Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and approved by the Ethics Committee of First Affiliated Hospital of Zhengzhou University (Approval number 2019-KY-174).

For tumor xenograft model, 2 × 10^6^ indicated UMUC3 and T24 cells were injected subcutaneously on the right side of the dorsum (*n* = 6 for each group). The tumor diameters were measured each week. Tumor volumes were calculated with the formula: V = 1/2 × A × B2. The mice were sacrificed after 6 weeks and tumors were analyzed.

Cell growth curve and colony-formation assay {#Sec9}
--------------------------------------------

Two thousand indicated cells were seeded in each well of a six-well plate and cultured for 10 days. The colonies were fixed with 4% paraformaldehyde and stained with crystal violet.

RNA extraction and quantitative reverse-transcriptase PCR {#Sec10}
---------------------------------------------------------

Cell total RNA was extracted using RNeasy kit (Qiagen) as manufacturer's instructions. First strand cDNA was synthesis using QuantiTect Reverse Transcription kit (Qiagen). qRT-PCR was performed using SBBR GREEN PCR Master Mix (Applied Biosystems) and detected with ABI 7900 System. Relative mRNA expression was calculated using the ΔΔCt equations. The primers used for ACSS genes detection by RT-qPCR are as following:

ACSS3:

Forward primer: 5′-TGGACCAAAACGCTGGAGAAC-3′

Reverse primer: 5′-ACGATCAACGGCATTGTAACA-3′

ACSS2:

Forward primer: 5′-AAAGGAGCAACTACCAACATCTG-3′

Reverse primer: 5′-GCTGAACTGACACACTTGGAC-3′

ACSS1:

Forward primer: 5′-CACAGGACAGACAACAAGGTC-3′

Reverse primer: 5′-CCTGGGTATGGACGATGCC-3′

Western blotting {#Sec11}
----------------

Western blot experiments was performed as previously described^[@CR24]^. Briefly, protein was extracted with RIPA buffer (Byotime) supplemented with protease inhibitor cocktail (Roche). Total protein concentration was quantified with BCA Protein Assay Kit (Thermo). An equal amount of total proteins were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membrane (Millipore). Then block the membrane with 5% non-fat milk, incubated with primary antibodies at 4 °C overnight and followed by secondary antibody for 1 h. The primary antibodies used were as follows: anti-ACSS1 (Invitrogen, PA5-59392), anti-ACSS2 (Cell Signaling Technology, 3568 S), anti-ACSS3 (Invitrogen, PA5-80305), anti-Tubulin (Proteintech, 66031--1), anti-acetyl-histone H4 (Millipore, 06--598), anti-histone H3 (CST, 4499), anti-acetyl-histone H3 (Millipore, 06--599), and anti-histone H4 (CST, 13919).

Clinical samples and immunohistochemistry {#Sec12}
-----------------------------------------

This project was approved by the Ethics Committee of First Affiliated Hospital of Zhengzhou University (Approval number 2019-KY-174) and patients enrolled were informed of the scientific usage of the samples. Serial sections of formalin-fixed, paraffin-embedded tissues from 60 patients were obtained between September 2014 and March 2017. The routine immunohistochemistry were performed as previously described^[@CR25]^. Slices were immunostained using anti-ACSS3 (Invitrogen, PA5-80305) antibody. DAB (diaminobenzidine) stainings were performed with an HRP kit (UltraTek, USA) according to the manufacturer's instructions. Stained specimens were visualized using a general optical microscope with a camera (Axiovert 100 M, Germany).

Immunofluorescence and confocal microscopy {#Sec13}
------------------------------------------

Cells were planted on the glass coverslips a day in advance. After transfected with indicated plasmids, the cells were fixed with 4% paraformaldehyde. The cell membranes were p permeabilized with NP40, then blocked with blocking buffer for 1 h. After incubation with primary antibody against Myc-tag (Proteintech, 16286-1-AP) for overnight, cells were washed with Phosphate-Buffered Saline (PBS)-Tween and incubated with Alexa Fluor 488 donkey anti-rabbit secondary antibody (Invitrogen, R37118). Mitochondrial were stained with MitoTracker (Invitrogen, M22426) for 30 min and nuclei were stained with DAPI (Beyotime, C1002) for 10 min. The slides were observed using the Lecia Tcs SP8 confocal microscope.

Spheroid growth assay {#Sec14}
---------------------

Spheroid formation assay were performed as previously described^[@CR26]^, cells were digested with trypsin, and cultured with 2% matrigel in 96-well ultralow attachment plates (Costar). Spheroid formation was initiated by centrifugation at 850 × *g* for 10 min and the spheroids were analyzed at the indicated time points. Spheroids were treated with ethanol (control) or doxycycline 48 h. At indicated time points, images were captured by a general optical microscope with a camera (Axiovert 100 M, Germany). Spheroid volume was calculated based on image analysis by area determination using image J software.

Statistical analysis {#Sec15}
--------------------

Statistical analysis was performed with GraphPad Prism 5.0. (GraphPad Software). Experiments were performed at least in triplicates and error bars stands for SD. Two-tailed Student's t-test was performed to determine the significance of paired data. One-way analysis of variance for quantitative data from grouped DataSets. *P*-value \< 0.05 was considered significant. \**P* \< 0.05; \*\**P* \< 0.01, and \*\*\**P* \< 0.001. A log-rank test was performed to compare tumor-free survival. *P*-values less than 0.05 were considered statistically significant.

Results {#Sec16}
=======

Lipogenic AcCoA metabolism is altered in BLCA under stress {#Sec17}
----------------------------------------------------------

As FASN is closely related to the carcinogenesis, we therefore analyzed the role FASN in BLCA. We first analyzed the growth of BLCA cells treated with FASN inhibitor C75. Our data revealed that C75 did not affect the growth of normal bladder urothelial cells (SV-HUC-1) cultured with 10% serum (full serum) or 1% serum (low serum). Although the growth of BLCA cells (UMUC3 and T24) was not affected by C75 treatment in full serum, we observed that the growth of BLCA cells cultured in low serum was significantly inhibited by C75 administration (Fig. [1a](#Fig1){ref-type="fig"}). Moreover, we found that BLCA cells cultured with low serum were more sensitive to another FASN inhibitor, AZ22, as revealed by improvement of IC~50~ (Fig. [1b](#Fig1){ref-type="fig"}). As AcCoA is originated from alternative pathways (Fig. [1c](#Fig1){ref-type="fig"}) and hypoxic status mimics the in vivo lipid metabolic conditions^[@CR5],[@CR6]^, we next evaluated the fatty acids metabolism in BLCA under hypoxia. We first analyzed the contribution of various precursors of lipogenic AcCoA and found that utilization of acetate (^13^C labeled) was dramatically increased in BLCA cells under hypoxia (Fig. [1d](#Fig1){ref-type="fig"}). Moreover, via isotopic labeling of glucose, glutamine, and acetate, our results revealed that the proportion of lipogenic AcCoA generated from glucose were largely reduced, whereas the proportion of lipogenic AcCoA generated from glutamine and acetate were increased significantly in BLCA cells (Fig. [1e](#Fig1){ref-type="fig"}).Fig. 1AcCoA is generated through alternative pathway in BLCA cells under metabolic stress.**a** Sensitivity of normal bladder urothelial cells (SV-HUC-1) and bladder cancer cells to FASN inhibitor C75 in high (10%) or low (1%) serum levels. **b** Sensitivity of bladder cancer cells to FASN inhibitor AZ22 in high (10%) or low (1%) serum levels as revealed by pIC~50~. **c** Schematic of lipogenic AcCoA production. **d** Percentage of lipogenic AcCoA generation from acetate (labeled by ^13^C) under normoxia (21% O~2~) or hypoxia (1% O~2~) culture. **e** Sources of lipogenic AcCoA (labeled by ^13^C) under normoxia (21% O~2~) or hypoxia (1% O~2~) culture.

ACSS3 is responsible for lipogenic AcCoA synthesis in BLCA cells under metabolic stress {#Sec18}
---------------------------------------------------------------------------------------

Previous study demonstrated that ACSS2 participated in lipid metabolism in breast cancer cells under hypoxic conditions^[@CR5]^. Here we analyzed the role another ACSS family member plays, ACSS3, in BLCA. We first analyzed the expression levels of ACSS3 cultured with 10% serum or 1% serum under normal oxygen concentration, and found that the expression of all three members of ACSS family were not dramatically changed (Fig. [2a, b](#Fig2){ref-type="fig"}). However, when BLCA cells were cultured under hypoxia condition, the expression level of ACSS2 and ACSS3 in BLCA cells cultured with 1% serum were significantly increased in comparison with the expression level in BLCA cells cultured with 10% serum (Fig. [2a, b](#Fig2){ref-type="fig"}), indicating that metabolic stress, especially hypoxia, triggered the expression of ACSS2 and ACSS3 in BLCA cells. As ACSS2 has been reported to response to metabolic stress, we focused on the function of ACSS3. We utilized siRNA to downregulated ACSS3 expression in BLCA cells and both of the two siRNAs achieved considerable knockdown efficiency (Fig. [2c](#Fig2){ref-type="fig"}). Meanwhile, the protein level of ACSS1 and ACSS2 were not changed when ACSS3 was knocked down by siRNA (Fig. [2c](#Fig2){ref-type="fig"}). Colony-formation experiments revealed that downregulation of ACSS3 attenuated the number of colonies formed in both normoxia and hypoxia conditions in UMUC3 and T24 cells (Fig. [2d](#Fig2){ref-type="fig"}). Cell number counting revealed that ACSS3 knockdown significantly inhibited cell proliferation in both normoxia and hypoxia conditions (Fig. [2e](#Fig2){ref-type="fig"}), suggesting that ACSS3 was responsible for BLCA cell growth under metabolic stress. Importantly, a significant reduction was found in the lipogenic AcCoA from ^13^C-acetate (Fig. [2f](#Fig2){ref-type="fig"}). Meanwhile, labeling from ^13^C-glucose and ^13^C-glutamine were both increased (Fig. [2g](#Fig2){ref-type="fig"}) under indicated conditions. In order to clarify the localization of ACSS3, ACSS3-Myc plasmid was constructed and expressed in T24 cells. The expression of ACSS3 was detected through immunofluorescence staining assay using antibody against Myc-tag. As shown in Fig. [2h](#Fig2){ref-type="fig"}, myc signals were observed co-localized with MitoTracker, suggesting the colocalization with mitochondria.Fig. 2ACSS3 is induced under metabolic stress and facilitate BLCA cell growth.**a** ACSS1, ACSS2, and ACSS3 mRNA expression levels in BLCA cells under normoxia (21% O~2~) or hypoxia (1% O~2~) culture with 10% or 1% serum levels. **b** ACSS1, ACSS2, and ACSS3 protein expression levels in BLCA cells under normoxia (21% O~2~) or hypoxia (1% O~2~) culture with 10% or 1% serum levels. **c** ACSS1, ACSS2, and ACSS3 protein expression levels in BLCA cells transfected with control of ACSS3 siRNA. **d** Colony formed from BLCA cells transfected with control of ACSS3 siRNA under indicated culture situations. **e** Cell number of BLCA cells transfected with control of ACSS3 siRNA under indicated culture situations after 48 h incubation. **f** Percentage of lipogenic AcCoA generation from acetate (labeled by ^13^C) in BLCA cells transfected with control of ACSS3 siRNA under hypoxia (1% O~2~) culture. **g** Percentage of lipogenic AcCoA generation from glutamine or glucose (labeled by ^13^C) in BLCA cells transfected with control of ACSS3 siRNA under hypoxia (1% O~2~) culture. **h** Subcellular localization of ACSS3-Myc expressed in T24 cells. ACSS3 was detected with anti-myc antibody. Mitochondria was stained with MitoTracker.

ACSS3 is crucial for histone acetylation in BLCA cells {#Sec19}
------------------------------------------------------

To determine the net uptake of acetate by cancer cells, a delicate measurement has been developed previously^[@CR5]^ and we utilized this measurement to study the role ACSS3 in lipid metabolism in BLCA cancer cells. Our results showed that ACSS3 knockdown attenuated acetate consumption from the medium (Fig. [3a](#Fig3){ref-type="fig"}). Meanwhile, more endogenous acetate was released to the medium suggesting that ACSS3 (Fig. [3a](#Fig3){ref-type="fig"}) is required for the utilization of endogenous acetate in cancer cells. We next calculated the ratio of acetate release and consumption in BLCA cells transfected with control siRNA or ACSS3 siRNA and found that this ratio was markedly increased in BLCA cells transfected with ACSS3 siRNA (Fig. [3b](#Fig3){ref-type="fig"}), further suggesting that ACSS3 facilitated acetate metabolism in cancer cells. We then studied the role of ACSS3 under metabolic stress. Interestingly, under normal culture status, downregulation of ACSS3 did not affect the levels of acetylated histone H3 and H4 (Fig. [3c](#Fig3){ref-type="fig"}). However, under metabolic stress, ACSS3 was required for maintaining the levels of acetylated histone H3 and H4 (Fig. [3c](#Fig3){ref-type="fig"}). Moreover, our data also revealed that metabolic stress induced a significant increase in histone acetylation in BLCA cells, which was aborted in ACSS3 knockdown cells (Fig. [3c](#Fig3){ref-type="fig"}), further indicating that ACSS3 is crucial for histone acetylation in BLCA cells.Fig. 3ACSS3 is required for acetate utilization and histone acetylation.**a** Consumption of medium acetate and release of cytoplasmic acetate in BLCA cells transfected with control of ACSS3 siRNA under hypoxia (1% O~2~) culture. **b** Ratio of acetate release and consumption in BLCA cells transfected with control of ACSS3 siRNA under hypoxia (1% O~2~) culture. **c** Level of histone H3, acetylated histone H3, histone H4, and acetylated histone H4 in BLCA cells cultured in indicated conditions. Right panel are quantified results of protein expression levels.

ACSS3 silencing inhibits spheroid and tumor growth {#Sec20}
--------------------------------------------------

To further analyze the role ACSS3 in BCLA, we generated stable cell lines in which ACSS3 could be silenced by doxycycline administration. We first validated that doxycycline was able to induce ACSS3 silence in the stable cell lines (Fig. [4a](#Fig4){ref-type="fig"}). We then cultured these cells as spheroids in 10% or 1% serum with or without the administration of doxycycline. Importantly, our results showed that only in low serum culture, downregulation of ACSS3 resulted in significant impairment of spheroids formation in UMUC3 and T24 cells (Fig. [4b](#Fig4){ref-type="fig"}). In addition, BLCA cells were inoculated subcutaneously into nude mice and half of the mice were treated with doxycycline on the 7th day post inoculation. The tumor growth of the xenografts formed by BLCA cells expressing ACSS3 shRNA was significantly inhibited in comparison with xenografts formed by BLCA cells expressing control shRNA or xenografts formed by BLCA cells without doxycycline treatment (Fig. [4c](#Fig4){ref-type="fig"}). Hence, our data indicated an oncogenic role of ACSS3 in BLCA.Fig. 4ACSS3 is required for spheroid and xenografts formation.**a** Induction of ACSS3 knockdown by doxycycline in BLCA cells. **b** Spheroid formation in BLCA cells stably transfected with control of ACSS3 shRNA with or without doxycycline administration under high serum or low serum culture. **c** Xenografts formed by BLCA cells stably transfected with control of ACSS3 shRNA with or without doxycycline administration under high serum or low serum culture. Right panels are measurements of tumor volumes at indicated time points.

We then analyzed the expression pattern of ACSS3 in clinical samples (Table [1](#Tab1){ref-type="table"}). We found that the both mRNA and protein levels of ACSS3 were significantly upregulated in BLCA samples compared with adjacent controls (Fig. [5a, b](#Fig5){ref-type="fig"}). We analyzed the staining intensity of the immunochemistry staining of ACSS3 and found that the staining intensity of ACSS3 was significantly higher in samples from BLCA patients in both stage I and stage II plus stage III (Fig. [5c, d](#Fig5){ref-type="fig"}). Moreover, BLCA patients with lower ACSS3 expression were entitled with longer overall survival time (Fig. [5e](#Fig5){ref-type="fig"}). Taken together, our analysis illustrated that the expression of ACSS3 was statistically elevated in BLCA patients and high ACSS3 level predicted poor outcome of BCLA prognosis.Table 1Correlation between ACSS3 expression and clinicopathological characteristics of bladder cancer patients.ParametersTotalACSS3 expression*P*-valueLow (*n* = 30)High (*n* = 30)Gender0.194Male331419Female271611Age (years)0.519\<591275≥59482325Tumor stage0.793Ta,T11156T2--T4492524TNM stage0.010\*S-I28199S-II + III321121Grade0.004\*G1332211G2--G327819Tumor size0.781\<3 cm19910≥3 cm412120Lymph node metastasis0.000\*Absent32923Present28217Distant metastasis0.028\*Absent482127Present1293Fig. 5ACSS3 is elevated in BLCA patient samples.**a** ACSS3 mRNA expression levels in BLCA patient samples and adjacent normal tissues. **b** Representative immunohistochemistry images of ACSS3 staining in BLCA patient samples and adjacent normal tissues. **c** ACSS3 protein intensities in BLCA patient samples and adjacent normal tissues. **d** ACSS3 protein intensities in stage I or stage II + III BLCA patient samples and adjacent normal tissues. **e** Overall survival of BLCA patients with higher or low ACSS3 mRNA expression levels.

Discussions {#Sec21}
===========

Cancer cells adapt to nutrient-deprived tumor microenvironment during progression via adjusting the level and function of metabolic enzymes^[@CR26]^. Several metabolic altered pathways are involved in bladder tumorigenesis^[@CR27]^. With the advancement of multi-omics analysis, de novo identification of oncogenes have been carried out in various types of cancers, including BLCA^[@CR28]^. A most recent multi-omics study has shown that fatty acid metabolism plays a central role in facilitating the progress of BLCA^[@CR29]^. Moreover, another report showed that fibroblast growth factor receptor 3 promotes the cleavage and activation of sterol regulatory element-binding protein 1, which is the key regulator of lipogenesis, which in turn facilitates the BLCA cell growth^[@CR30]^. Here we first analyzed the utilization of acetate in BLCA confronting environmental stress and found that BLCA cell lines altered the way of generation, which is in line with previous reports showing that cancer cells adapted to nutrient-deprived tumor microenvironment^[@CR5],[@CR17],[@CR31]^.

As it has been shown that ACSS family members were critical for alternative utilization of acetate in cancer cells^[@CR5],[@CR26]^, we suspected the role ACSS3 in BLCA cells under metabolic stress. As a member of ACSS enzyme family, ACSS3 is the least studied. ACSS1 is the main mitochondrial enzyme and ACSS2 mainly functions in nucleus and cytosol. Here we demonstrated that in BLCA cells, ACSS3 is localized in mitochondria and functions as an oncogene to promote lipid synthesis and histone acetylation through the use of acetate.

Importantly, our data showed that the expression level of ACSS3 were significantly upregulated in BLCA cell lines upon metabolic stress, suggesting an oncogenic role of ACSS3 in BLCA. Downregulation of ACSS3 significantly suppressed the growth of BLCA cells in vitro and in vivo. Indeed, previous report uncovered a higher expression of ACSS3 in tumor comparing to normal parental lesions and downregulation of ACSS3 inhibits progression of gastric cancer^[@CR13]^. In hepatocellular carcinoma, ACSS3 was expressed in mitochondria and specifically recognized a subtype of hepatocellular carcinoma (namely iHCC2, which represents poor clinical survival rate)^[@CR9]^, suggesting that the presence of ACSS3 may be noxious in hepatocellular carcinoma as well. Taken together, these data indicated an oncogenic role of ACSS3 even under routine culture conditions. Interestingly, methylation level of ACSS3 was found to be associated with prognosis of neuroblastoma patients^[@CR32]^. It is of special significance to further determine the role of methylated ACSS3 in the progression of BLCA.

Interestingly, we found an upregulation of histone acetylation under low serum and hypoxic conditions in BLCA, which is consistent with the notion that fatty acid biosynthesis is significantly elevated in hypoxia and low serum conditions in breast cancer cell lines^[@CR5]^, and the majority of histone acetylation is derived from fatty acid carbon^[@CR33]^. Importantly, our results showed that the upregulated acetylation of histone H3 and histone H4 were significantly impaired in BLCA cells with downregulated ACCS3 level. Our data revealed that ACSS3 is required for the utilization of both environmental and intracellular acetate, which is identical to the role of ACSS2 in breast cancer cells^[@CR5]^. As ACSS3 is mainly localized in mitochondria, the mechanisms of using acetate to promote histone acetylation should be different from that of ACSS2, which could directly converts the acetate to nuclear acetyl-CoA. The possible cause might be recycling of endogenous acetate, which needs further exploration.

In addition to the data illustrating that inhibition of ACSS3 suppressed xenograft formation in mice, we also analyzed clinical samples and found that the expression of ACSS3 was significantly increased in BLCA samples compared with adjacent normal tissues. Moreover, patients with higher ACSS3 suffered from poorer overall survival. As the correlation of high ACSS3 expression with poor survival can be validated in multiple online database (data not shown), it is of huge potential to further analysis of the relationship between ACSS3 expression and overall BLCA patient's survival has great potential. Therefore, ACSS3 might be a promising prognosis marker for BLCA patients.

Taken together, our data demonstrated that fatty acid metabolism is altered in BLCA cells confronting nutrient stress in an ACSS-dependent manner. More importantly, ACSS3 facilitates the acetate utilization and histone acetylation in metabolic stressed BLCA cells and promotes BLCA cell growth. Our data revealed an oncogenic role of ACSS3 and fatty acid in BLCA, and provide a promising target in metabolic pathway for BLCA treatment.
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